Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is an inherited metabolic disorder that belongs to a group of disorders associated with defective β-oxidation of fatty acids. The underlying disorder involves dysfunction of the enzyme acyl-CoA dehydrogenase, which is required for the oxidation of medium-chain fatty acids. This results in the body's inability to break down certain fatty acids, which causes their accumulation and can lead to serious clinical manifestations including hypoglycemia, respiratory distress, cardiomyopathy, and, in severe cases, death.
History of the disease and interesting historical facts
Medium-chain acyl-CoA dehydrogenase deficiency was first described in the medical literature in 1983, when researchers identified the genetic defect associated with the disorder. Since then, much attention has been devoted to understanding the molecular basis of the disorder. In the 1990s, significant advances were made in diagnostics, allowing more accurate identification of affected patients based on genetic testing. The establishment of newborn screening programs in several countries has helped in early detection and timely intervention, significantly improving the long-term prognosis.
Epidemiology
Medium-chain acyl-CoA dehydrogenase deficiency occurs with an incidence of approximately 1 in 15,000 to 1 in 25,000 births worldwide. Incidence data are gradually being considered insufficient, as the disease may be under-recognized due to difficult-to-recognize clinical manifestations in later life. Studies suggest that the diversity of mutations in the ACADM gene may be associated with a higher incidence of the disease in certain ethnic groups, which requires further research.
Genetic predisposition to this disease
Medium-chain acyl-CoA dehydrogenase deficiency is caused by mutations in the ACADM gene, located on chromosome 1p31. Mutations can range from point mutations to deletions affecting functional regions of the gene responsible for synthesizing the acyl-CoA dehydrogenase enzyme. More than 100 different mutations are known to contribute to the development of the disease. Carrying one abnormal copy of the gene can lead to stages of deficiency that manifest themselves during stresses such as starvation or infection.
Risk factors for the development of this disease
Risk factors for developing medium-chain acyl-CoA dehydrogenase deficiency are primarily hereditary. The main risks include:
- Heredity: presence of patients in the family history.
- Ethnicity: Increased risks among certain populations, such as African Americans or people with a Covenant Region.
- Age of parents: higher risks for parents over 35 years old.
The pathology can also be aggravated by external factors, such as infectious diseases and the lack of essential elements in food, which are critical for fat metabolism.
Diagnosis of this disease
Diagnosis of medium-chain acyl-CoA dehydrogenase deficiency is quite complex and often involves several steps and methods:
- Main symptoms: Usually appear in the first days or weeks of life and may include hypoglycemic episodes, lethargy, vomiting and seizures.
- Laboratory tests: Carnitine levels, increased medium-chain metabolites in urine and blood may indicate the disease.
- Radiological examinations: MRI or ultrasound of the heart can reveal cardiomyopathy developing against the background of the disease.
- Other types of diagnostics: molecular genetic studies to determine mutations in the ACADM gene.
- Differential diagnosis: It is necessary to exclude other metabolic disorders with similar features, such as other forms of fatty acid β-oxidation dysfunction.
Treatment
Treatment for medium-chain acyl-CoA dehydrogenase deficiency is aimed at managing symptoms and preventing acute events:
- General treatment: includes restriction or elimination of medium-chain fatty acids from the diet.
- Pharmacological treatment: May include the use of carnitine to improve metabolism and prevent the accumulation of toxic intermediates.
- Surgical treatment: may be required if complications such as cardiomyopathy develop.
- Other treatments: supportive therapy, such as diet adapted to the patient's needs.
List of medications used to treat this disease
The main drugs used to treat medium-chain acyl-CoA dehydrogenase deficiency include:
- Carnitine: regulates fatty acid metabolism.
- Glucose: Used to prevent hypoglycemia.
- Metabolic stimulants: In some cases, additional medications may be used to improve the patient's general condition.
Disease monitoring
Monitoring of patients with medium-chain acyl-CoA dehydrogenase deficiency requires regular monitoring of:
- Control stages: regular tests for carnitine and metabolite levels in the blood.
- Prognosis: if it helps to alleviate symptoms and organize treatment correctly, many patients achieve normal development.
- Complications: Cardiomyopathy, hypoglycemia, and delayed psychomotor development are common.
Age-related features of the disease
Medium-chain acyl-CoA dehydrogenase deficiency manifests itself differently in different age groups:
- Newborns: often have initial manifestations of the disease with hypoglycemia and vomiting.
- Children: May develop developmental delays and periodic crises.
- Adults: Some may be asymptomatic, but flare-ups may occur with stress or infections.
Questions and Answers
- What is medium-chain acyl-CoA dehydrogenase deficiency? It is a hereditary disease associated with a disorder of the metabolism of medium-chain fatty acids, which leads to their accumulation in the body.
- How is this disease diagnosed? Diagnosis includes assessment of clinical symptoms, laboratory tests for carnitine and metabolite levels, and genetic testing.
- What are the chances of recovery? Timely diagnosis and treatment allow most patients to achieve normal development and minimize the manifestations of the disease.
- What complications may arise? Major complications include cardiomyopathy, metabolic crises and developmental delay.
- What treatment is offered to patients with this pathology? Treatment includes restriction of medium-chain fats in the diet, use of carnitine, and correction of hypoglycemia.
